GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Upstream Bio Inc (NAS:UPB) » Definitions » ROCE %

UPB (Upstream Bio) ROCE % : -33.14% (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Upstream Bio ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Upstream Bio's annualized ROCE % for the quarter that ended in Sep. 2024 was -33.14%.

Upstream Bio ROCE % Historical Data

The historical data trend for Upstream Bio's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Upstream Bio ROCE % Chart

Upstream Bio Annual Data
Trend Dec22 Dec23
ROCE %
-175.52 -64.54

Upstream Bio Quarterly Data
Dec22 Jun23 Sep23 Dec23 Jun24 Sep24
ROCE % Get a 7-Day Free Trial - - -51.79 - -33.14

Upstream Bio ROCE % Calculation

Upstream Bio's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-40.114/( ( (18.478 - 4.856) + (117.198 - 6.515) )/ 2 )
=-40.114/( (13.622+110.683)/ 2 )
=-40.114/62.1525
=-64.54 %

Upstream Bio's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=-75.572/( ( (244.511 - 10.244) + (232.7 - 10.874) )/ 2 )
=-75.572/( ( 234.267 + 221.826 )/ 2 )
=-75.572/228.0465
=-33.14 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Upstream Bio  (NAS:UPB) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Upstream Bio ROCE % Related Terms

Thank you for viewing the detailed overview of Upstream Bio's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Upstream Bio Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Upstream Bio Inc (NAS:UPB) » Definitions » ROCE %
Comparable Companies
Traded in Other Exchanges
N/A
Address
890 Winter Street, Suite 200, Waltham, MA, USA, 02451
Website
https://www.upstreambio.com
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases.